Media coverage about Genomic Health (NASDAQ:GHDX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genomic Health earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.5897141799389 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
GHDX has been the topic of several research reports. Canaccord Genuity lowered their target price on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Cowen reissued a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a report on Friday, September 1st. Jefferies Group reissued a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Thursday, September 14th. Finally, Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $32.67.
Shares of Genomic Health (NASDAQ:GHDX) opened at $29.82 on Friday. Genomic Health has a 12-month low of $26.37 and a 12-month high of $34.02.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
What are top analysts saying about Genomic Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health Inc. and related companies.